Dechra Pharmaceuticals PLC
DCHPF · OTC
6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | |
|---|---|---|---|---|
| Revenue | $762 | $682 | $608 | $515 |
| % Growth | 11.7% | 12.1% | 18% | – |
| Cost of Goods Sold | $335 | $297 | $262 | $224 |
| Gross Profit | $426 | $385 | $346 | $292 |
| % Margin | 56% | 56.4% | 56.9% | 56.6% |
| R&D Expenses | $61 | $36 | $32 | $28 |
| G&A Expenses | $359 | $179 | $151 | $135 |
| SG&A Expenses | $359 | $179 | $151 | $135 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $75 | $70 |
| Operating Expenses | $420 | $215 | $259 | $233 |
| Operating Income | $6 | $96 | $84 | $52 |
| % Margin | 0.8% | 14% | 13.8% | 10.1% |
| Other Income/Exp. Net | -$42 | -$18 | -$13 | -$18 |
| Pre-Tax Income | -$36 | $78 | $74 | $41 |
| Tax Expense | -$8 | $19 | $19 | $7 |
| Net Income | -$28 | $58 | $56 | $34 |
| % Margin | -3.7% | 8.5% | 9.1% | 6.6% |
| EPS | -0.24 | 0.54 | 0.51 | 0.33 |
| % Growth | -144.4% | 5.9% | 54.5% | – |
| EPS Diluted | -0.24 | 0.53 | 0.51 | 0.33 |
| Weighted Avg Shares Out | 113 | 108 | 108 | 103 |
| Weighted Avg Shares Out Dil | 114 | 109 | 109 | 103 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $9 | $0 |
| Interest Expense | $44 | $12 | $10 | $12 |
| Depreciation & Amortization | $90 | $89 | $16 | $14 |
| EBITDA | $87 | $179 | $162 | $131 |
| % Margin | 11.4% | 26.2% | 26.6% | 25.4% |